Research conducted at the University of Queensland could contribute to the development of a vaccine and cure for West Nile virus and Dengue fever. Led by associate professor Alexander Khromykh, a team of researchers from UQ's School of Molecular and Microbial Sciences identified a novel characteristic of the virus family to which these diseases belong.
The team found all flaviviruses produced a small molecule which, among other functions, controlled the host's response to viral infection. This molecule, called a subgenomic noncoding ribonucleic acid (sfRNA), is a part of the virus genome.
"To develop new and effective antiviral strategies, we have to know as much as possible about the virus, or virus family, that we are fighting," Khromykh said. "As sfRNA is produced by all flaviviruses we tested so far, targeting it with an antiviral therapy may be effective for the whole range of flaviviruses. By using reverse genetic engineering we were able to generate viruses that do not produce this sfRNA and showed that these engineered viruses are no longer able to kill their hosts or elicit disease symptoms. These engineered viruses offer great potential as vaccine candidates as they are expected to elicit an antiviral immune response similar to the normal virus infection without causing a disease."
Khromykh said by studying mice infected with these engineered West Nile viruses, the team learned more about how the body attempted to combat a flavivirus infection.
The part of the virus the infected cells in the body are unsuccessful in destroying forms the sfRNA, which helps the virus to kill cells and cause potentially deadly diseases, he said.
"We identified sfRNA as a potential antiviral target for the large group of medically important viruses," Khromykh said. "Moreover, the knowledge obtained from our studies with West Nile virus should be readily applicable for designing anti-viral drugs and engineering similar vaccine candidates for other medically important flaviviruses."
Funded by the National Health and Medical Research Council, this study will be published in the December issue of the journal Cell Host & Microbe.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.